News und Analysen
LivaNova Board Appoints J. Christopher Barry as New Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
LivaNova to Announce Third-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: TR-1 Notification of Major Holdings
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC